The user is starting Dutasteride mesotherapy and seeks advice on whether to apply the solution immediately after microneedling or wait 12-24 hours. They couldn't find instructions for first-timers.
A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.
The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutis verticis gyrata with minoxidil and TRT are raised.
The conversation discusses managing seborrheic dermatitis (sebderm) and male pattern baldness (MPB) with treatments like finasteride, coal tar shampoo, Nizoral, and oral minoxidil. Users suggest dietary changes, regular shampooing, and using antifungal products to control sebderm before considering minoxidil.
A user on dutasteride for hair loss noticed hair regrowth on their head but a significant reduction in body hair growth. They plan to switch to finasteride and dutasteride and are considering testosterone replacement therapy but are concerned about its effects on hair growth.
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.
A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.
A 36-year-old is experiencing underwhelming results from derma stamping for hair thinning, using needle lengths of 0.5mm to 0.75mm. They are considering increasing needle length, taking a break, or pairing the treatment with rosemary oil.
The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.
The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.
Trans woman experiencing thinning hair despite low testosterone and finasteride use seeks possible causes and solutions. Current treatments include finasteride, spironolactone, estradiol, vitamins, and microneedling; minoxidil not tried due to concerns about dependence and side effects.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
A trans man experiencing hair loss after starting testosterone treatment has seen positive results using topical minoxidil and finasteride, though his hair remains thin. He is considering continuing his current treatment and exploring additional options like microneedling and Breezula, while acknowledging the impact of testosterone on hair loss.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.
Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.
The post discusses using at-home Dutasteride mesotherapy for hair loss, combined with topical minoxidil, microneedling, and a red laser cap. The user reports initial shedding, thicker hair, and a temporary dip in libido as side effects.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Dutasteride mesotherapy is being discussed as a hair loss treatment, with some users not seeing results and considering adding oral finasteride and minoxidil. Dutasteride injections are used as a complement to oral treatments, not as a standalone solution.
A 29-year-old is using oral minoxidil, finasteride, hormone replacement therapy (HRT), and microneedling for hair regrowth. They started balding at 20, worsened at 25, and are transitioning with testosterone blockers.
A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.
The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.
A user is considering combining oral and topical dutasteride to lower scalp DHT more effectively and is seeking advice on this approach. They are thinking about doing a patch test on their mid scalp.
The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
The user stopped using finasteride due to side effects and began treatment with Pyrilutamide, while continuing minoxidil, topical melatonin, dermarolling, and Nizoral. They had a second hair transplant to improve their frontal hairline and will report back on the results of the new treatment regimen.
The user lost ground on oral finasteride and plans to switch to topical finasteride/minoxidil and microneedling. They are curious if topical treatments are more effective than oral ones.
Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.
Dutasteride mesotherapy is discussed as a potentially effective hair loss treatment with no sexual side effects, requiring less frequent application than daily pills. However, it is not widely popular due to limited availability, high cost, and skepticism about its effectiveness.